Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 5, 2004

View Archived Issues

KI-105, a novel HSGAG-mimetic compound

In vitro evaluation of the effects of DX-88 during CPB surgery

Novel DPP-IV inhibitors identified by Kotobuki researchers

Lundbeck claims new KCNQ channel activators for epilepsy and other disorders

New opioid antagonists and their use as antiobesity agents

Two novel series of PPARdelta agonists developed at Ono

New analgesic agents targeting neuropeptide FF receptors

New SGLT2 inhibitors claimed by Yamanouchi and Kotoboki

Banyu scientists prepare and test new glucokinase activators

Novel 5-HT2C receptor ligands and their use described in GSK patent

Senetek signs letter of intent to acquire IGI

ABR-215757 enters phase I trials in Sweden

Velcade designated fast track drug for relapsed & refractory mantle cell lymphoma

QVAR in Easi-Breathe inhaler launched in U.K.

MediGene concludes license agreement for cancer-killing herpes simplex viruses

Biogen Idec advances Neublastin into development for neuropathic pain

Second stage of CoFactor phase II study given green light

ChemGenex plans phase II study of Quinamed in prostate cancer

NeuGene antisense drugs shows efficacy against Ebola virus in vivo

Equity financing at StemCells to fund study in Batten disease

Femara approved for post-tamoxifen treatment of early breast cancer

FDA approves new Xenical labeling

BioVisioN achieves milestone in Novo Nordisk collaboration

All endpoints met in multiple ascending dose study of ISA-247

7TM Pharma selects preclinical candidate for obesity

Novel potent and orally active HIV integrase inhibitor described by Merck

Bacterial TTPS inhibitors reported by Johnson & Johnson

DA-7911 reported to improve synovial thickness in refractory RA

Sildenafil shows promise in the management of complications secondary to systemic sclerosis

LJP-394 maintains efficacy in SLE patients concomitantly treated with immunosuppressants

Effective sedation achieved with Aquavan Injection for endoscopic procedures

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...